1.The Korean Rectal Cancer Multidisciplinary Committee Clinical Practice Guidelines for Rectal Cancer version 2.0
Hyo Seon RYU ; Hyun Jung KIM ; Dong Hyun KANG ; Yoo-Kang KWAK ; Han Deok KWAK ; Yoon-Hye KWON ; Dalyon KIM ; Baek-Hui KIM ; Jae Hyun KIM ; Ji Hun KIM ; Jin Won KIM ; Tae Hyung KIM ; Hae Young KIM ; Soo Min NAM ; Gyoung Tae NOH ; Jun Woo BONG ; Nak Song SUNG ; Seon Hui SHIN ; Kil-Yong LEE ; Sung Chul LEE ; Sea-Won LEE ; Jung Won LEE ; Jong Min LEE ; Myung Hoon IHN ; Joo Han LIM ; Woong Bae JI ; Dae Hee PYO ; Young Ki HONG ; Jung-Myun KWAK ;
Annals of Coloproctology 2026;42(1):4-33
Rectal cancer, which accounts for approximately 40% of colorectal cancers, remains a major clinical concern. Recent advances in diagnostic imaging, surgical techniques, radiotherapy, and systemic treatment have steadily improved rectal cancer outcomes. Considering this, the Korean Rectal Cancer Multidisciplinary (KRCM) Committee has aimed to provide clinicians and policymakers with up-to-date, evidence-based clinical practice guidelines to support optimal decision-making, reflecting current evidence, the Korean healthcare context, and patient values and preferences. The Clinical Practice Guidelines for Rectal Cancer version 2.0 were developed through multidisciplinary collaboration with related academic societies, building upon and updating the KRCM Clinical Practice Guidelines version 1.0 (titled “Multidisciplinary guidelines for the management of rectal cancer”). These consensus guidelines of the KRCM were established based on a comprehensive literature review, evidence synthesis, with recommendation development guided by the GRADE (Grading of Recommendations Assessment, Development and Evaluation) methodology, and consideration of applicability in real-world clinical practice under the national health insurance system. Each recommendation has been presented with its strength and level of evidence.
2.Better Chemotherapeutic Response of Small Cell Lung Cancer in Never Smokers than in Smokers
Ha-Young PARK ; Hyung-Joo OH ; Hwa Kyung PARK ; Joon-Young YOON ; Chang-Seok YOON ; Bo Gun KHO ; Tae-Ok KIM ; Hong-Joon SHIN ; Chul-Kyu PARK ; Yong-Soo KWON ; Yu-Il KIM ; Sung-Chul LIM ; Young-Chul KIM ; In-Jae OH
Tuberculosis and Respiratory Diseases 2025;88(2):334-341
Background:
Small cell lung cancer (SCLC) is called ‘smoker’s disease’ because it is strongly associated with smoking and most cases occur in smokers. However, it can also occur in never smokers. We investigated the clinical features of never smokers with SCLC and compared their treatment outcomes with those of smokers with SCLC.
Methods:
We retrospectively reviewed the clinical data of patients who had proven SCLC and had received chemotherapy at a single cancer center between July 2002 and April 2021.
Results:
Of 1,643 patients, 1,416 (86.2%) were enrolled in this study. A total of 162 (11.4%) and 1,254 (88.6%) patients were never smokers and smokers, respectively. There were more female never smokers than smokers (n=130; 80.2% vs. 79, 6.3%, p=0.000), and the incidence of ischemic heart disease was lower among never smokers than among smokers (4/1,416, [2.5%] vs. 83/1,416 [6.6%], p=0.036). Never smokers showed less symptoms at diagnosis than smokers (80.9% vs. 87.2%, p=0.037); however, they showed more toxicity after first-line treatment (61.7% vs. 47.8%, p=0.001). The objective response rate (ORR) was significantly higher in never smokers (74.1% vs. 59.6%, p=0.000). In the multivariate analysis, never smoking and second-line treatment were associated with a better ORR. However, progression-free survival and overall survival were not significantly different between never smokers and smokers.
Conclusion
In conclusion, never smokers accounted for 11.4% of patients with SCLC. They had distinguishing clinical characteristics and showed better chemotherapeutic responses than smokers.
3.Concomitant Rotator Cuff Tear with Frozen Shoulder: A Contemplation on the Necessity and Legitimacy of Magnetic Resonance Imaging Stratified by Age
Hsien-Hao CHANG ; Tae-Hwan YOON ; Joon-Ryul LIM ; Yong-Min CHUN
Clinics in Orthopedic Surgery 2025;17(3):453-459
Background:
Frozen shoulder (FS) is often accompanied by a rotator cuff tear (RCT), but it can be challenging to diagnose a concomitant RCT without imaging studies. Therefore, having practical criteria to identify patients requiring imaging studies at initial presentation with FS would lead to more cost-effective use of these studies. This study investigated the relationship between RCT and stiffness in patients with FS and whether this relationship was modified by patient age.
Methods:
This study included 540 adults with shoulder pain who had ≥ 10° of limited passive range of motion in forward flexion, compared to the contralateral side. Patients were categorized into 2 groups depending on the degree of forward flexion stiffness: overhead stiffness (OHS) group, patients with ≥ 110° forward flexion (n = 349); and non-OHS group, patients with forward flexion < 110° (n = 191). The presence of concomitant RCT was determined by magnetic resonance imaging and compared between groups before and after stratification by age.
Results:
The OHS group had increased odds of concomitant RCT, compared to the non-OHS group (odds ratio [OR], 4.99; 95% CI, 3.36–7.42). OHS was also significantly associated with a more severe grade of RCT (no tear, partial-thickness tear, or full-thickness tear) (OR, 4.42; 95% CI, 3.05–6.39). The odds of RCT in the OHS group, compared to the non-OHS group, increased with age (50–59 years: OR, 3.83; 95% CI, 1.96–7.48; 60–69 years: OR, 5.94; 95% CI, 3.14–11.26; and 70–79 years: OR, 7.67; 95% CI, 2.71–21.66).
Conclusions
Patients with FS and forward flexion range of motion ≥ 110° (i.e., OHS) at initial presentation had approximately 5-fold higher odds of concurrent RCT than patients with non-OHS. Moreover, in patients aged 50 years or above, these odds increased up to almost 8-fold. Therefore, we recommend confirming the rotator cuff integrity with magnetic resonance imaging in patients with FS and OHS.
4.Better Chemotherapeutic Response of Small Cell Lung Cancer in Never Smokers than in Smokers
Ha-Young PARK ; Hyung-Joo OH ; Hwa Kyung PARK ; Joon-Young YOON ; Chang-Seok YOON ; Bo Gun KHO ; Tae-Ok KIM ; Hong-Joon SHIN ; Chul-Kyu PARK ; Yong-Soo KWON ; Yu-Il KIM ; Sung-Chul LIM ; Young-Chul KIM ; In-Jae OH
Tuberculosis and Respiratory Diseases 2025;88(2):334-341
Background:
Small cell lung cancer (SCLC) is called ‘smoker’s disease’ because it is strongly associated with smoking and most cases occur in smokers. However, it can also occur in never smokers. We investigated the clinical features of never smokers with SCLC and compared their treatment outcomes with those of smokers with SCLC.
Methods:
We retrospectively reviewed the clinical data of patients who had proven SCLC and had received chemotherapy at a single cancer center between July 2002 and April 2021.
Results:
Of 1,643 patients, 1,416 (86.2%) were enrolled in this study. A total of 162 (11.4%) and 1,254 (88.6%) patients were never smokers and smokers, respectively. There were more female never smokers than smokers (n=130; 80.2% vs. 79, 6.3%, p=0.000), and the incidence of ischemic heart disease was lower among never smokers than among smokers (4/1,416, [2.5%] vs. 83/1,416 [6.6%], p=0.036). Never smokers showed less symptoms at diagnosis than smokers (80.9% vs. 87.2%, p=0.037); however, they showed more toxicity after first-line treatment (61.7% vs. 47.8%, p=0.001). The objective response rate (ORR) was significantly higher in never smokers (74.1% vs. 59.6%, p=0.000). In the multivariate analysis, never smoking and second-line treatment were associated with a better ORR. However, progression-free survival and overall survival were not significantly different between never smokers and smokers.
Conclusion
In conclusion, never smokers accounted for 11.4% of patients with SCLC. They had distinguishing clinical characteristics and showed better chemotherapeutic responses than smokers.
5.Better Chemotherapeutic Response of Small Cell Lung Cancer in Never Smokers than in Smokers
Ha-Young PARK ; Hyung-Joo OH ; Hwa Kyung PARK ; Joon-Young YOON ; Chang-Seok YOON ; Bo Gun KHO ; Tae-Ok KIM ; Hong-Joon SHIN ; Chul-Kyu PARK ; Yong-Soo KWON ; Yu-Il KIM ; Sung-Chul LIM ; Young-Chul KIM ; In-Jae OH
Tuberculosis and Respiratory Diseases 2025;88(2):334-341
Background:
Small cell lung cancer (SCLC) is called ‘smoker’s disease’ because it is strongly associated with smoking and most cases occur in smokers. However, it can also occur in never smokers. We investigated the clinical features of never smokers with SCLC and compared their treatment outcomes with those of smokers with SCLC.
Methods:
We retrospectively reviewed the clinical data of patients who had proven SCLC and had received chemotherapy at a single cancer center between July 2002 and April 2021.
Results:
Of 1,643 patients, 1,416 (86.2%) were enrolled in this study. A total of 162 (11.4%) and 1,254 (88.6%) patients were never smokers and smokers, respectively. There were more female never smokers than smokers (n=130; 80.2% vs. 79, 6.3%, p=0.000), and the incidence of ischemic heart disease was lower among never smokers than among smokers (4/1,416, [2.5%] vs. 83/1,416 [6.6%], p=0.036). Never smokers showed less symptoms at diagnosis than smokers (80.9% vs. 87.2%, p=0.037); however, they showed more toxicity after first-line treatment (61.7% vs. 47.8%, p=0.001). The objective response rate (ORR) was significantly higher in never smokers (74.1% vs. 59.6%, p=0.000). In the multivariate analysis, never smoking and second-line treatment were associated with a better ORR. However, progression-free survival and overall survival were not significantly different between never smokers and smokers.
Conclusion
In conclusion, never smokers accounted for 11.4% of patients with SCLC. They had distinguishing clinical characteristics and showed better chemotherapeutic responses than smokers.
6.Better Chemotherapeutic Response of Small Cell Lung Cancer in Never Smokers than in Smokers
Ha-Young PARK ; Hyung-Joo OH ; Hwa Kyung PARK ; Joon-Young YOON ; Chang-Seok YOON ; Bo Gun KHO ; Tae-Ok KIM ; Hong-Joon SHIN ; Chul-Kyu PARK ; Yong-Soo KWON ; Yu-Il KIM ; Sung-Chul LIM ; Young-Chul KIM ; In-Jae OH
Tuberculosis and Respiratory Diseases 2025;88(2):334-341
Background:
Small cell lung cancer (SCLC) is called ‘smoker’s disease’ because it is strongly associated with smoking and most cases occur in smokers. However, it can also occur in never smokers. We investigated the clinical features of never smokers with SCLC and compared their treatment outcomes with those of smokers with SCLC.
Methods:
We retrospectively reviewed the clinical data of patients who had proven SCLC and had received chemotherapy at a single cancer center between July 2002 and April 2021.
Results:
Of 1,643 patients, 1,416 (86.2%) were enrolled in this study. A total of 162 (11.4%) and 1,254 (88.6%) patients were never smokers and smokers, respectively. There were more female never smokers than smokers (n=130; 80.2% vs. 79, 6.3%, p=0.000), and the incidence of ischemic heart disease was lower among never smokers than among smokers (4/1,416, [2.5%] vs. 83/1,416 [6.6%], p=0.036). Never smokers showed less symptoms at diagnosis than smokers (80.9% vs. 87.2%, p=0.037); however, they showed more toxicity after first-line treatment (61.7% vs. 47.8%, p=0.001). The objective response rate (ORR) was significantly higher in never smokers (74.1% vs. 59.6%, p=0.000). In the multivariate analysis, never smoking and second-line treatment were associated with a better ORR. However, progression-free survival and overall survival were not significantly different between never smokers and smokers.
Conclusion
In conclusion, never smokers accounted for 11.4% of patients with SCLC. They had distinguishing clinical characteristics and showed better chemotherapeutic responses than smokers.
7.Concomitant Rotator Cuff Tear with Frozen Shoulder: A Contemplation on the Necessity and Legitimacy of Magnetic Resonance Imaging Stratified by Age
Hsien-Hao CHANG ; Tae-Hwan YOON ; Joon-Ryul LIM ; Yong-Min CHUN
Clinics in Orthopedic Surgery 2025;17(3):453-459
Background:
Frozen shoulder (FS) is often accompanied by a rotator cuff tear (RCT), but it can be challenging to diagnose a concomitant RCT without imaging studies. Therefore, having practical criteria to identify patients requiring imaging studies at initial presentation with FS would lead to more cost-effective use of these studies. This study investigated the relationship between RCT and stiffness in patients with FS and whether this relationship was modified by patient age.
Methods:
This study included 540 adults with shoulder pain who had ≥ 10° of limited passive range of motion in forward flexion, compared to the contralateral side. Patients were categorized into 2 groups depending on the degree of forward flexion stiffness: overhead stiffness (OHS) group, patients with ≥ 110° forward flexion (n = 349); and non-OHS group, patients with forward flexion < 110° (n = 191). The presence of concomitant RCT was determined by magnetic resonance imaging and compared between groups before and after stratification by age.
Results:
The OHS group had increased odds of concomitant RCT, compared to the non-OHS group (odds ratio [OR], 4.99; 95% CI, 3.36–7.42). OHS was also significantly associated with a more severe grade of RCT (no tear, partial-thickness tear, or full-thickness tear) (OR, 4.42; 95% CI, 3.05–6.39). The odds of RCT in the OHS group, compared to the non-OHS group, increased with age (50–59 years: OR, 3.83; 95% CI, 1.96–7.48; 60–69 years: OR, 5.94; 95% CI, 3.14–11.26; and 70–79 years: OR, 7.67; 95% CI, 2.71–21.66).
Conclusions
Patients with FS and forward flexion range of motion ≥ 110° (i.e., OHS) at initial presentation had approximately 5-fold higher odds of concurrent RCT than patients with non-OHS. Moreover, in patients aged 50 years or above, these odds increased up to almost 8-fold. Therefore, we recommend confirming the rotator cuff integrity with magnetic resonance imaging in patients with FS and OHS.
8.Concomitant Rotator Cuff Tear with Frozen Shoulder: A Contemplation on the Necessity and Legitimacy of Magnetic Resonance Imaging Stratified by Age
Hsien-Hao CHANG ; Tae-Hwan YOON ; Joon-Ryul LIM ; Yong-Min CHUN
Clinics in Orthopedic Surgery 2025;17(3):453-459
Background:
Frozen shoulder (FS) is often accompanied by a rotator cuff tear (RCT), but it can be challenging to diagnose a concomitant RCT without imaging studies. Therefore, having practical criteria to identify patients requiring imaging studies at initial presentation with FS would lead to more cost-effective use of these studies. This study investigated the relationship between RCT and stiffness in patients with FS and whether this relationship was modified by patient age.
Methods:
This study included 540 adults with shoulder pain who had ≥ 10° of limited passive range of motion in forward flexion, compared to the contralateral side. Patients were categorized into 2 groups depending on the degree of forward flexion stiffness: overhead stiffness (OHS) group, patients with ≥ 110° forward flexion (n = 349); and non-OHS group, patients with forward flexion < 110° (n = 191). The presence of concomitant RCT was determined by magnetic resonance imaging and compared between groups before and after stratification by age.
Results:
The OHS group had increased odds of concomitant RCT, compared to the non-OHS group (odds ratio [OR], 4.99; 95% CI, 3.36–7.42). OHS was also significantly associated with a more severe grade of RCT (no tear, partial-thickness tear, or full-thickness tear) (OR, 4.42; 95% CI, 3.05–6.39). The odds of RCT in the OHS group, compared to the non-OHS group, increased with age (50–59 years: OR, 3.83; 95% CI, 1.96–7.48; 60–69 years: OR, 5.94; 95% CI, 3.14–11.26; and 70–79 years: OR, 7.67; 95% CI, 2.71–21.66).
Conclusions
Patients with FS and forward flexion range of motion ≥ 110° (i.e., OHS) at initial presentation had approximately 5-fold higher odds of concurrent RCT than patients with non-OHS. Moreover, in patients aged 50 years or above, these odds increased up to almost 8-fold. Therefore, we recommend confirming the rotator cuff integrity with magnetic resonance imaging in patients with FS and OHS.
9.Concomitant Rotator Cuff Tear with Frozen Shoulder: A Contemplation on the Necessity and Legitimacy of Magnetic Resonance Imaging Stratified by Age
Hsien-Hao CHANG ; Tae-Hwan YOON ; Joon-Ryul LIM ; Yong-Min CHUN
Clinics in Orthopedic Surgery 2025;17(3):453-459
Background:
Frozen shoulder (FS) is often accompanied by a rotator cuff tear (RCT), but it can be challenging to diagnose a concomitant RCT without imaging studies. Therefore, having practical criteria to identify patients requiring imaging studies at initial presentation with FS would lead to more cost-effective use of these studies. This study investigated the relationship between RCT and stiffness in patients with FS and whether this relationship was modified by patient age.
Methods:
This study included 540 adults with shoulder pain who had ≥ 10° of limited passive range of motion in forward flexion, compared to the contralateral side. Patients were categorized into 2 groups depending on the degree of forward flexion stiffness: overhead stiffness (OHS) group, patients with ≥ 110° forward flexion (n = 349); and non-OHS group, patients with forward flexion < 110° (n = 191). The presence of concomitant RCT was determined by magnetic resonance imaging and compared between groups before and after stratification by age.
Results:
The OHS group had increased odds of concomitant RCT, compared to the non-OHS group (odds ratio [OR], 4.99; 95% CI, 3.36–7.42). OHS was also significantly associated with a more severe grade of RCT (no tear, partial-thickness tear, or full-thickness tear) (OR, 4.42; 95% CI, 3.05–6.39). The odds of RCT in the OHS group, compared to the non-OHS group, increased with age (50–59 years: OR, 3.83; 95% CI, 1.96–7.48; 60–69 years: OR, 5.94; 95% CI, 3.14–11.26; and 70–79 years: OR, 7.67; 95% CI, 2.71–21.66).
Conclusions
Patients with FS and forward flexion range of motion ≥ 110° (i.e., OHS) at initial presentation had approximately 5-fold higher odds of concurrent RCT than patients with non-OHS. Moreover, in patients aged 50 years or above, these odds increased up to almost 8-fold. Therefore, we recommend confirming the rotator cuff integrity with magnetic resonance imaging in patients with FS and OHS.
10.Better Chemotherapeutic Response of Small Cell Lung Cancer in Never Smokers than in Smokers
Ha-Young PARK ; Hyung-Joo OH ; Hwa Kyung PARK ; Joon-Young YOON ; Chang-Seok YOON ; Bo Gun KHO ; Tae-Ok KIM ; Hong-Joon SHIN ; Chul-Kyu PARK ; Yong-Soo KWON ; Yu-Il KIM ; Sung-Chul LIM ; Young-Chul KIM ; In-Jae OH
Tuberculosis and Respiratory Diseases 2025;88(2):334-341
Background:
Small cell lung cancer (SCLC) is called ‘smoker’s disease’ because it is strongly associated with smoking and most cases occur in smokers. However, it can also occur in never smokers. We investigated the clinical features of never smokers with SCLC and compared their treatment outcomes with those of smokers with SCLC.
Methods:
We retrospectively reviewed the clinical data of patients who had proven SCLC and had received chemotherapy at a single cancer center between July 2002 and April 2021.
Results:
Of 1,643 patients, 1,416 (86.2%) were enrolled in this study. A total of 162 (11.4%) and 1,254 (88.6%) patients were never smokers and smokers, respectively. There were more female never smokers than smokers (n=130; 80.2% vs. 79, 6.3%, p=0.000), and the incidence of ischemic heart disease was lower among never smokers than among smokers (4/1,416, [2.5%] vs. 83/1,416 [6.6%], p=0.036). Never smokers showed less symptoms at diagnosis than smokers (80.9% vs. 87.2%, p=0.037); however, they showed more toxicity after first-line treatment (61.7% vs. 47.8%, p=0.001). The objective response rate (ORR) was significantly higher in never smokers (74.1% vs. 59.6%, p=0.000). In the multivariate analysis, never smoking and second-line treatment were associated with a better ORR. However, progression-free survival and overall survival were not significantly different between never smokers and smokers.
Conclusion
In conclusion, never smokers accounted for 11.4% of patients with SCLC. They had distinguishing clinical characteristics and showed better chemotherapeutic responses than smokers.

Result Analysis
Print
Save
E-mail